Ou Tangjing(R) (Engligliflozin Tablets) new indication for adult patients with heart failure with preserved ejection fraction has submitted an application for registration in China

Shanghai, October 11, 2021/PRNewswire/ - On September 30, 2021, Boehringer Ingelheim-Eli Lilly jointly announced that it has formally submitted its Diabetes Alliance's SGLT2 to the China National Medical Products Administration Center for Drug Evaluation Inhibitor Otangjing® (generic name: Enpagliflozin tablets) is used for the registration application of new indications for adult patients with heart failure with preserved ejection fraction

Heart failure is a set of complex clinical syndromes caused by abnormal changes in the structure and/or function of the heart caused by various reasons, which cause ventricular contraction and/or diastolic dysfunction.

The registration application of Otangjing® for the indications of heart failure in adult patients with preserved ejection fraction is based on the EMPEROR-Preserved Phase III clinical trial.

Dr.

Dr.

[i] GBD 2016 Disease and Injury Incidence and Prevalence Collaborators.

[ii] Gurwitz JH, Magid DJ, Smith DH, Goldberg RJ, McManus DD, Allen LA, Saczynski JS, Thorp ML, Hsu G, Sung SH, Go AS.

[iii] China-HF

[iv] Shiba N, Nochioka K, Miura M, Kohno H, Shimokawa H; CHART-2 Investigators.

[v] REPRESENT-HF study.

[vi] Shah SJ, Borlaug B, Kitzman D, et al.

[vii] Ponikowski P, Anker SD, AlHabib KF, et al.

Source: Boehringer Ingelheim